Interleukin-1 and the NLRP3 inflammasome in COVID-19: Pathogenetic and therapeutic implications - eBioMedicine
NLRP3 and pyroptosis blockers for treating inflammatory diseases: Trends in Pharmacological Sciences
JCI - Confounding role of tumor necrosis factor in cryopyrin-associated periodic syndromes
Cryo-sensitive aggregation triggers NLRP3 inflammasome assembly in cryopyrin-associated periodic syndrome | eLife
Berberine Directly Targets the NEK7 Protein to Block the NEK7–NLRP3 Interaction and Exert Anti-inflammatory Activity | Journal of Medicinal Chemistry
NLRP3 - Ventus Therapeutics
Frontiers | Regulation of the NLRP3 Inflammasome by Post-Translational Modifications and Small Molecules
Pharmacological targeting of NLRP3 deubiquitination for treatment of NLRP3-associated inflammatory diseases | Science Immunology
The NLRP3 inhibitor MCC950 inhibits... | Wellcome Open Research
NLRP3 Phosphorylation Is an Essential Priming Event for Inflammasome Activation - ScienceDirect
PKD-mediated NLRP3 activation pathway and the relevant CAPS mutations.... | Download Scientific Diagram
Frontiers | Genetic Hearing Loss Associated With Autoinflammation
IJMS | Free Full-Text | The NLRP3 Inflammasome: Relevance in Solid Organ Transplantation
T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells | Science
CAPS and NLRP3 | SpringerLink
Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction | Pharmacological Reviews
MCC950 | NLRP3 inflammasome inhibitor | InvivoGen
Therapeutic effect of NLRP3 inhibition on hearing loss induced by systemic inflammation in a CAPS-associated mouse model - eBioMedicine
NLRP3 leucine-rich repeats control induced and spontaneous inflammasome activation in cryopyrin-associated periodic syndrome - Journal of Allergy and Clinical Immunology
Frontiers | Pharmacological Inhibitors of the NLRP3 Inflammasome
INFLAMMASOME INHIBITORS - 21st Century Miracle Drugs: Spotlight on Clinical NLRP3 Inflammasome Inhibitors
Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease - ScienceDirect
